IRVINE, Calif. & LIEGE, Belgium--(BUSINESS WIRE)--Regulatory News:
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced results for Q4 and full year 2011.
